Abstract: Provided is a compound containing a peptide of at least 4 amino acids including the following sequence: His Phe* Arg, wherein Phe* represents phenylalanine or a halogenated derivative of phenylalanine the said peptide being conjugated with thioctic acid, dihydrolioic acid, or N-lipoyl-lysine, in the form of the corresponding salts, esters or amides. In particular, compounds with anti-allergic and anti-inflammatory activities on the one had, and melanogenesis-activating activities on the other, are described.

Abstract: The present invention relates to a D 25 polysaccharide compound whose lipid has been partially removed and to its derivatives, wherein at least 85% by weight, preferably 90% of the compound, exists in aqueous solution in monomeric form. The 30 kD molecular weight polysaccharide compound extracted from the membrane proteoglycan of the bacterium Klebsiella pneumoniae is mentioned in particular. The amount of palmitic fatty acids which is bound to it in esterified form does not exceed 0.01% by weight of the compound and the amount of palmitic fatty acids which is associated with it in the free form does not exceed 0.1% by weight of the compound.

Abstract: The invention relates to a polysaccharide derivative which is an amide, an ester, an ether, a salt or a quaternary ammonium derivative of D.25 with an amine, an acid or an alcohol.

Abstract: The present invention relates to a membrane polysaccharide of bacterial origin having the following quantitative analytical composition:______________________________________ galactose content 66 .+-. 6% content of hexoses other than galactose <1% hexosamine (glucosamine) content 8.5 .+-. 2% amino acid content 5 .+-. 2% fatty acid content <1% nucleic acid content <0.005% protein content <0.03% and molecular weight: 90,000 .+-. 10,000.

Abstract: The present invention relates to a method of preparing bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram-negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product.The products obtained are useful as a medicament.

Abstract: This invention relates to a non-specific immunostimulating preparation for the treatment of immunodeficits, such as those encountered in leprosy and cancer, characterized in that it contains as sole active principle one or more bacterial ribosomal RNA's extracted from the following strains:Klebsiella pneumoniaeSerratia marcescens

Abstract: The present invention relates to an improved process for the preparation of plasminogen activator.This is a process for separating a plasminogen activator according to U.S. Pat. No. 3,998,947 characterized in that it comprises at least the following stages:(i) selective adsorption of the said activator on a support with specific affinity comprising soluble fragments of fibrin covalently bonded to an insoluble matrix; and(ii) elution of the activator from the fibrin bearing the adsorbed activator.The plasminogen activator obtained is useful in the prevention and treatment of thrombosis.

Abstract: The present invention relates to new chemical compounds which can be used as inhibitors of dental plaque, and orally-acceptable compositions thereof, combinations thereof with known compounds having an inhibitory action on the formation of dental plaque, such as biguanidines, and method of treating therewith for the prevention of dental plaque or tartar and dental caries.The new compounds have the general formula ##STR1## in which R.sub.1 = H or alkylR.sub.2 = ch.sub.2 oh, alkyl carboxylate, ##STR2## and R.sub.2 is in 2 or 3 position.Compositions containing these active principles are useful in particular in the preventive treatment of periodontopathies and odontopathies and in the field of oral-dental hygiene.

Abstract: A process for obtaining a plasminogen activator involves treating an acetone extract powder of organs of animals, such as the lungs and kidneys of pigs, calves, bullocks, horses, lambs or sheep or the ovaries of porcine, bovine or ovine animals, by suspension in an aqueous saline solution, taking up the precipitate obtained in an aqueous saline solution of greater ionic strength and lower pH-value, decanting the solution and precipitating therefrom at acidic pH by adding a salt or an organic solvent, further taking up the precipitate obtained in water or a saline solution, followed by repeated precipitation by adding a salt at a somewhat higher pH-value, finally taking up the precipitate obtained in water and dialyzing the solution, and optionally purifying the solution obtained.The activator obtained may be used as a medicament.